Estetra (Mithra assets)→Gedeon Richter
Acquisition · Cash · RICHTER · announced Jun 12, 2024
Announced
Jun 12, 2024
Closed
Jun 12, 2024
Economics
Cash()
Pre-deal · pre-deal mark: 2024, year precision · Gedeon Richter press release — Estetra acquisition, 2024
Enterprise value ~€175M (~$195M) including assumed net debt
Target
Estetra (Mithra assets)
Contraception · Clinical / therapeutic
HQ Liège, Belgium · Founded 2012
Estetrol (E4) platform — native estrogen for contraception (ESTELLE) and menopause (DONESTA), acquired from Mithra Pharmaceuticals
- Gedeon Richter press release (Jun 12, 2024)
- Budapest Stock Exchange filing
Acquirer
Gedeon Richter (RICHTER)
Reproductive Health
HQ Budapest, Hungary
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Acquired estetrol (E4) native estrogen platform — ESTELLE (contraception, marketed) and DONESTA (menopause, in development); enables US/Japan expansion of women's healthcare business
Evidence ladder
Secondary (press / IR)
Gedeon Richter press release (Jun 12, 2024)
Tertiary (trade / analyst)
Budapest Stock Exchange filing
Limitations
- Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
- Enterprise value ~€175M (~$195M) including assumed net debt
- Pre-deal valuation sourced from: Gedeon Richter press release — Estetra acquisition, 2024. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Other verified deals by Gedeon Richter
Acquirer program history not already listed as a valuation peer or adjacency row.
| Target | Acquirer | Announced | Value | Sector |
|---|---|---|---|---|
| Celmatix | Gedeon Richter | Mar 3, 2026 | Undisclosed | Fertility |
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Estetra (Mithra assets) (Contraception). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.